• Home
• Reports
• Companies

• Partnering Search
• Pay-per-Click
• Profiling

• Out-licensing
• In-licensing
• Services

• PL Intelligence
• Deal Negotiation
• Deals review

• Press releases
• Events
• Newsletter

Latest: Watch here for details of new products and services.

Innovaro Pharmalicensing
is a division of
Innovaro Europe Ltd

— HONG KONG, July 28

HONG KONG, July 28 /PRNewswire/ -- OrbusNeich today announced the addition of the Sapphire NC coronary dilatation catheter to its product line-up with the receipt of CE Mark approval.

A non-compliant balloon, Sapphire NC has controlled growth of only 0.6% per atmosphere of pressure over the working pressure range for controlled dilatations. Furthermore, it has a high 22 atmospheres rated burst pressure for confident treatment of tough, calcified lesions and for post-stent dilatation.

"Sapphire NC is a reliable, easily deliverable, high performance balloon with assured results when used during percutaneous coronary intervention," said Huay-Cheem Tan, M.D., of National University Hospital in Singapore.

Sapphire NC combines advanced precision and material engineering technologies to provide optimum reliability and deliverability. The balloon catheter's HIST (HIgh Speed Tracking) tip enables flexible tracking along the guidewire, while OrbusNeich's TIFO (Tight Fold) processing results in a slender profile for enhanced crossability through tight lesions. Sapphire NC is available in a wide range of sizes for precise dilatation to match popular stent lengths.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Scoreflex(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

As a global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Editor's Note: Product graphics available on request

Web site: http://www.OrbusNeich.com

Get the Flash Player to see this rotator.

Press releases: Innovaro Pharmalicensing current industry press releases.

Products:	Partnering Search	Pay-per-Click	Company Profiling	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us